<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961804</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2012-02</org_study_id>
    <nct_id>NCT01961804</nct_id>
  </id_info>
  <brief_title>PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma</brief_title>
  <acronym>PREVACT</acronym>
  <official_title>Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <brief_summary>
    <textblock>
      The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist
      treatment leads to a high risk of bleeding.

      Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to
      reverse anticoagulation with concomitant administration of prothrombin complex concentrates
      (PCCs) and vitamin K.

      However, even if a reversion is performed, the prognostic of post-traumatic intracranial
      bleeding remain bad.

      The investigators hypothesize that, for patients admitted in an emergency department after a
      minor head trauma and receiving anticoagulant treatment, a systematic preventive reversion
      with PCCs can lead to a significant reduction of intracranial haemorrhage and can also
      improve the neurological prognostic of patients versus the current strategy.

      PREVACT will test this hypothesis, in an open label, randomized, multicentre, clinical trial
      involving 400 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of intracranial bleeding diagnosed in CT scan</measure>
    <time_frame>24 hours +/- 4 hours</time_frame>
    <description>This primary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric measure of intracranial haemorrhage</measure>
    <time_frame>CT scan performed 24 hours +/-4 after inclusion</time_frame>
    <description>This secondary outcome measure will be analyse in a centralised place by two neuro-radiologist in blind of the randomised group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a decrease in their autonomy</measure>
    <time_frame>3 months</time_frame>
    <description>A loss of at least one point in the Glasgow Outcome Score Extended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient having a systemic or neurologic ischemic attacks</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coagulation; Intravascular</condition>
  <condition>Craniocerebral Trauma</condition>
  <condition>Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preventive reversion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Realise a preventive reversion before performing any CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reversion</intervention_name>
    <description>Administration of prothrombin complex concentrates: KANOKAD before CT Scan</description>
    <arm_group_label>Actual recommendations</arm_group_label>
    <arm_group_label>Preventive reversion</arm_group_label>
    <other_name>KANOKAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission in an emergency departement for a recent and isolated minor head trauma with
             at least one of the following characteristic : a period of alteration in the level of
             consciousness, a period of loss of consciousness (&lt; 30 min), a posttraumatic amnesia,
             persistant posttraumatic headache, repeated vomitting (at least 2 episodes) or any
             other neurological sign such a convulsion or a localised neurological sign, wound of
             the scalp or the face testifying of the importance of the cranial trauma...

          -  Subject receiving anticoagulant treatment with anti-vitamin K for the treatment of
             atrial fibrillation (AF)

          -  Initial ED Glasgow Coma Scale (GCS) score of ≥13

          -  Achievable follow up

          -  Informed consent form signed by the patient or if he/she isn't able an emergency
             inclusion can be realised.

        Exclusion Criteria:

          -  Delay between the minor head trauma and the possible preventive PCC's administration &gt;
             6h

          -  Subject receiving anticoagulant treatment other than anti vitamin K (heparin,
             fondaparinux, dabigatran, rivaroxaban, apixaban...)

          -  Subject receiving anticoagulant treatment for other reason than a AF

          -  Subject on antiplatelet treatment (except the use of low dose of aspirin (≤ 100
             mg/day)

          -  Delocalised biology INR in capillary blood &lt; 1.5 if it's available (only in
             departement where this analyse is a usual practice)

          -  Haemorrhage or suspected haemorrhage other than intracranial which could led to a
             reversion of the anticoagulation

          -  Head trauma associated with one or further potential haemorrhagic traumatic lesions

          -  Subject who reject the use of products derived from human blood

          -  Women who are pregnant

          -  Subject with any condition that, as judged by the investigator, would place the
             subject at increased risk of harm if he/she participated in the study

          -  Subject without social security registered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROY Pierre-Marie, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TAZAROURTE Karim, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>UH Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROY Pierre-Marie, Professor</last_name>
    <phone>+33(2)-41-35-79-47</phone>
    <email>prevact@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TAZAROURTE Karim, Professor</last_name>
    <phone>+33(2)-41-35-79-47</phone>
    <email>prevact@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>TRINH DUC Albert, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROY Pierre Marie, PhD</last_name>
      <phone>+33 2 41 35 37 15</phone>
      <email>pmroy@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>GABLE Béatrice</last_name>
      <phone>+33 2 41 35 79 47</phone>
      <email>begable@chu-angers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>ROY Pierre Marie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SAVARY, Dr</last_name>
      <email>dsavary@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Beaumont sur Oise</name>
      <address>
        <city>Beaumont Sur Oise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AVICENNE</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Chateauroux</name>
      <address>
        <city>Chateauroux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ch Cholet</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHG du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ch Les Sables D'Olonne</name>
      <address>
        <city>Les Sables d'Olonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch Longjumeau</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hery ANDRIANJAFY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent JACQUIN, PhD</last_name>
      <email>laurent.jacquin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU METZ</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>HOFFMANN Mathieu, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chg Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LEVRAUT, PhD</last_name>
      <email>levraut.j@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chu Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>LARDEUR Jean Yves, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chu Saint Brieuc</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BRICE Christian, MD</last_name>
    </contact>
    <investigator>
      <last_name>BRICE Christian, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VERLEY Laurent, MD</last_name>
    </contact>
    <investigator>
      <last_name>VERLEY Laurent, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DEHOURS Emilie, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ch Versailles</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

